Relationship between plasma coenzyme Q 10, asymmetric dimethylarginine and arterial stiffness in patients with phenotypic or genotypic familial hypercholesterolemia on long-term statin therapy

Atherosclerosis

Volumn 218, Issue 1, 2011, Pages 188-193

  Young, Joanna M ^a,b   Molyneux, Sarah L ^c   Reinheimer, Annette M ^a   Florkowski, Christopher M ^a,c   Frampton, Christopher M ^b   Scott, Russell S ^a,b   George, Peter M ^c  

^a Diabetes Research Institute   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

Arterial stiffness; Asymmetric dimethylarginine; Augmentation index; Coenzyme Q 10; Familial hypercholesterolemia; Statin therapy

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; N(G),N(G) DIMETHYLARGININE; UBIDECARENONE;

ADULT; AMINO ACID BLOOD LEVEL; ARTERIAL STIFFNESS; ARTICLE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; INCREASED COENZYME Q10 BLOOD LEVEL; LIPID BLOOD LEVEL; LONG TERM CARE; MALE; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT; VITAMIN BLOOD LEVEL;

AGED; ARGININE; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUTATION; RECEPTORS, LDL; UBIQUINONE; VASCULAR STIFFNESS;

EID: 80052273662     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.04.034     Document Type: Article

References (32)

1. Goldstein J.L., Hobbs H.H., Brown M.S. Familial hypercholesterolaemia. The metabolic and molecular basis of inherited disease 2001, 2863-2913. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Smilde T.J., van Wissen S., Wollersheim H., et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001, 357:577-581.
3. Crane F.L Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001, 20:591-598.
4. Kawashiri M.A., Nohara A., Tada H., et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther 2008, 83:731-739.
5. Strey C.H., Young J.M., Molyneux S.L., et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 2005, 179:201-206.
6. Human J.A., Ubbink J.B., Jerling J.J., et al. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin Chim Acta 1997, 263:67-77.
7. Watts G.F., Castelluccio C., Rice-Evans C., et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993, 46:1055-1057.
8. Elmberger P.G., Kalen A., Lund E., et al. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. J Lipid Res 1991, 32:935-940.
9. Mabuchi H., Haba T., Tatami R., et al. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. Atheroscler Suppl 2004, 5:51-55.
10. Arnett D.K., Evans G.W., Riley W.A. Arterial stiffness: a new cardiovascular risk factor?. Am J Epidemiol 1994, 140:669-682.
11. Brown S.L., Raal F.J., Panz V.R., Stevens B.A., Veller M.G. High-dose atorvastatin therapy is required for significant improvement of endothelial function in heterozygous familial hypercholesterolaemic patients. Cardiovasc J S Afr 2004, 15:70-75.
12. Riggio S., Mandraffino G., Sardo M.A., et al. Pulse wave velocity and augmentation index, but not intima-media thickness, are early indicators of vascular damage in hypercholesterolemic children. Eur J Clin Invest 2010, 40:250-257.
13. Pitsavos C., Toutouzas K., Dernellis J., et al. Aortic stiffness in young patients with heterozygous familial hypercholesterolemia. Am Heart J 1998, 135:604-608.
14. Smilde T.J., van den Berkmortel F.W., Wollersheim H., et al. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest 2000, 30:473-480.
15. Laurie A.D., George P.M. Evaluation of high-resolution melting analysis for screening the LDL receptor gene. Clin Biochem 2009, 42:528-535.
16. WHO Human genetics DoNDP. Familial hypercholesterolaemia-report of a second WHO consultation 1999, WHO, Geneva.
17. Wilkinson I.B., Fuchs S.A., Jansen I.M., et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 1998, 16:2079-2084.
18. Molyneux S., Florkowski C., McGrane Y., Lever M., George P. Concentration response to the coenzyme Q10 supplement Q-Gel in human volunteers. Nutr Res 2007, 27:307-312.
19. Teerlink T., Nijveldt R.J., de Jong S., van Leeuwen P.A. Determination of arginine asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002, 303:131-137.
20. New Zealand Guidelines Group. Best practice evidence based guideline: the assessment and management of cardiovascular risk. Wellington, New Zealand; 2003.
21. Huijgen R., Kindt I., Verhoeven S.B., et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One 2010, 5:e9220.
22. Wilkinson I., Cockcroft J.R. Cholesterol, lipids and arterial stiffness. Adv Cardiol 2007, 44:261-277.
23. Sutton-Tyrrell K, Newman A., Simonsick E.M., et al. Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging, and body composition. Hypertension 2001, 38:429-433.
24. Wakabayashi I., Masuda H. Lipoprotein (a) as a determinant of arterial stiffness in elderly patients with type 2 diabetes mellitus. Clin Chim Acta 2006, 373:127-131.
25. Wilkinson I.B., Qasem A., McEniery C.M., et al. Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002, 105:213-217.
26. Soga J, Nakamura S., Nishioka K., et al. Relationship between augmentation index and flow-mediated vasodilation in the brachial artery. Hypertens Res 2008, 31:1293-1298.
27. Gomez-Marcos M.A., Recio-Rodriguez J.I., Patino-Alonso M.C., et al. Relationship between intima-media thickness of the common carotid artery and arterial stiffness in subjects with and without type 2 diabetes: a case-series report. Cardiovasc Diabetol 2011, 10:3.
28. Molyneux S.L., Florkowski C.M., Lever M., George P.M. Biological variation of coenzyme Q10. Clin Chem 2005, 51:455-457.
29. Bargossi A.M., Battino M., Gaddi A., et al. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Int J Clin Lab Res 1994, 24:171-176.
30. Tiano L., Belardinelli R., Carnevali P., et al. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur Heart J 2007, 28:2249-2255.
31. Belardinelli R, Mucaj A., Lacalaprice F., et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 2006, 27:2675-2681.
32. Hamilton S.J., Chew G.T., Watts G.F. Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care 2009, 32:810-812.